UBS analyst Ashwani Verma raised the firm’s price target on Neurocrine to $159 from $128 and keeps a Buy rating on the shares. The firm is bullish on Neurocrine’s prospering pipeline helping to ease concerns around the terminal-value of the pipeline as it expects $2.17B in peak sales from muscarinic platform and crinecerfont by 2035, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $164 from $157 at Guggenheim
- Neurocrine price target raised to $161 from $160 at Deutsche Bank
- Neurocrine price target raised to $106 from $100 at Piper Sandler
- Neurocrine price target raised to $154 from $150 at Canaccord
- Neurocrine price target raised to $140 from $116 at Mizuho
